PKN2
MOLECULAR TARGETprotein kinase N2
PKN2 (protein kinase N2) is targeted by 33 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting PKN2
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | tofacitinib | 4.65 | 104 |
| 2 | tozasertib | 4.33 | 75 |
| 3 | bosutinib | 4.08 | 58 |
| 4 | midostaurin | 3.85 | 46 |
| 5 | fasudil | 3.66 | 38 |
| 6 | nintedanib | 3.61 | 36 |
| 7 | baricitinib | 3.56 | 34 |
| 8 | y 27632 | 3.47 | 31 |
| 9 | tae 684 | 3.43 | 30 |
| 10 | dovitinib | 3.09 | 21 |
| 11 | jnj 7706621 | 3.09 | 21 |
| 12 | at 9283 | 3.09 | 21 |
| 13 | lestaurtinib | 3.04 | 20 |
| 14 | ruboxistaurin | 2.94 | 18 |
| 15 | r 406 | 2.83 | 16 |
| 16 | k 252a | 2.83 | 16 |
| 17 | crenolanib | 2.71 | 14 |
| 18 | kw 2449 | 2.64 | 13 |
| 19 | gsk 690693 | 2.64 | 13 |
| 20 | zotiraciclib | 2.56 | 12 |
| 21 | gsk 461364 | 2.40 | 10 |
| 22 | ripasudil | 2.40 | 10 |
| 23 | hydroxyfasudil | 2.40 | 10 |
| 24 | azd 7762 | 2.30 | 9 |
| 25 | su 014813 | 2.20 | 8 |
| 26 | y 39983 | 2.20 | 8 |
| 27 | rg 547 | 2.08 | 7 |
| 28 | hydroxyfasudil [Supplementary Concept] | 1.79 | 5 |
| 29 | ucn 01 | 1.79 | 5 |
| 30 | sar 407899 free base | 1.79 | 5 |
| 31 | alsterpaullone | 0.69 | 1 |
| 32 | Axitinib | 0.69 | 1 |
| 33 | Dasatinib | 0.69 | 1 |
About PKN2 as a Drug Target
PKN2 (protein kinase N2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 33 compounds with documented PKN2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
PKN2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.